Transgene

Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024

Retrieved on: 
Wednesday, March 6, 2024

Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster on updated data from the ongoing randomized Phase I trial of TG4050 at the American Association for Cancer Research Annual Meeting (AACR).

Key Points: 
  • Strasbourg, France, March 6, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster on updated data from the ongoing randomized Phase I trial of TG4050 at the American Association for Cancer Research Annual Meeting (AACR).
  • The AACR will take place in San Diego, California, USA, from April 5 to 10, 2024.
  • The abstract will be available on the AACR website April 5, 2024, at 3:00 p.m.
  • Transgene and NEC plan to continue the development of TG4050 in this indication with a Phase II extension of the trial expected to start in 2024.

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Monday, February 26, 2024

(the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.

Key Points: 
  • (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.
  • Financial results for the quarter ended December 31, 2023:
    Cash, cash equivalents, and investments totaled $594.1 million on December 31, 2023.
  • The Company recorded net product revenue of $42.1 million from sales of VYJUVEK during the quarter ended December 31, 2023.
  • For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the Securities and Exchange Commission.

NanoMosaic launches AAV gene therapy bioprocessing and manufacturing QC assays for simultaneous capsid & transgene interrogation with high standardization

Retrieved on: 
Wednesday, March 6, 2024

The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.

Key Points: 
  • The assays are seamlessly deployable across upstream and downstream stages of the gene therapy workflow, while harmonizing the data from bioprocessing to batch release QC.
  • "The objectives pursued by NanoMosaic are positive steps forward for a space desperate for a fit-for-purpose tool that can be standardized throughout the entire gene therapy development and manufacturing processes.
  • "NanoMosaic is excited to offer a unique solution to a challenging and fast-growing gene therapy market," said Qimin Quan, PhD, co-founder and Chief Scientific Officer.
  • NanoMosaic will feature the platform and unique gene therapy applications in a live broadcast scientific webinar alongside industry leaders on March 26, 2024, hosted by Genetic Engineering News (GEN).

Auditory Insight Explains Hearing Loss Gene Therapy for Children

Retrieved on: 
Wednesday, February 21, 2024

NEW HAVEN, Conn., Feb. 21, 2024 /PRNewswire/ -- Auditory Insight, a leading consultancy for the hearing healthcare industry, analyzes preliminary results for gene therapy clinical trials addressing deafness and hearing loss in its Q1 2024 Research Note.

Key Points: 
  • NEW HAVEN, Conn., Feb. 21, 2024 /PRNewswire/ -- Auditory Insight , a leading consultancy for the hearing healthcare industry, analyzes preliminary results for gene therapy clinical trials addressing deafness and hearing loss in its Q1 2024 Research Note.
  • In three sets of investigational clinical trials around the globe, gene therapy has transformed the hearing of children with a form of deafness from mutations in a gene called otoferlin.
  • She has advised gene therapy companies on surgeon, audiologist, and patient needs for gene therapy and genetic testing.
  • The trials also matter because they advance the learnings of scientists developing gene therapy for other forms of genetic hearing loss.

eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan

Retrieved on: 
Tuesday, February 13, 2024

eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.

Key Points: 
  • eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.
  • As part of a collaboration between the two companies, genetically engineered porcine cells developed by eGenesis were provided to PorMedTec for production using the somatic cell nuclear transfer, or cloning, process.
  • eGenesis and PorMedTec plan to jointly advance the development of genetically engineered organs in Japan to address the massive unmet need in the country, with an initial focus on kidney transplant.
  • “Cloning technology will enable the use of an alternative organ supply using genetically engineered porcine donors.

Be Biopharma to Present at Keystone Symposia on Emerging Cellular Therapies

Retrieved on: 
Thursday, January 25, 2024

Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced an oral presentation and poster presentation at the Keystone Symposia on Emerging Cellular Therapies meeting, held from January 22 to 25, 2024 in Santa Fe, New Mexico.

Key Points: 
  • Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced an oral presentation and poster presentation at the Keystone Symposia on Emerging Cellular Therapies meeting, held from January 22 to 25, 2024 in Santa Fe, New Mexico.
  • The data being presented support the utility of engineered B cell medicines (BCMs) across a broad range of applications.
  • “Gene and cell therapies have transformative potential to treat previously intractable diseases, but have barriers to adoption such as lack of durability, inability to re-dose, and requirement of preconditioning for engraftment.
  • Our BCM platform has the potential to address these barriers,” said Richard A. Morgan, Ph.D., Chief Scientific Officer, Be Bio.

Asimov launches LV Edge Packaging System to optimize lentivirus production

Retrieved on: 
Monday, January 29, 2024

BOSTON, Jan. 29, 2024 /PRNewswire/ -- Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.

Key Points: 
  • BOSTON, Jan. 29, 2024 /PRNewswire/ -- Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.
  • By removing the need to transiently transfect three out of the four GMP plasmids, the LV Edge Packaging System reduces manufacturing cost and supply chain risk without compromising speed to market.
  • The LV Edge Packaging System achieves high harvest titers of over 1E8 TU/mL across multiple chimeric antigen receptor (CAR) transgenes and enables tuneable transgene expression in the transduced cell.
  • For more information on the LV Edge Packaging System, please visit: www.asimov.com/ LV

eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor

Retrieved on: 
Thursday, January 18, 2024

The perfusion was performed using the eGenesis liver, EGEN-5784, connected to the OrganOx extracorporeal liver cross-circulation (ELC) device to enable circulation of the donor’s blood through the porcine liver.

Key Points: 
  • The perfusion was performed using the eGenesis liver, EGEN-5784, connected to the OrganOx extracorporeal liver cross-circulation (ELC) device to enable circulation of the donor’s blood through the porcine liver.
  • The efficacy of existing liver support options is limited, and patients in liver failure face a high risk of mortality.
  • For some patients, utilizing a human-compatible, genetically engineered porcine whole liver to support the function of a patient’s decompensated liver may provide time for the recovery of the patient’s native liver or time to obtain a liver transplant.
  • The genetically engineered porcine liver used in this study carried the same genetics as the porcine kidneys used in the landmark preclinical study recently published in Nature .

Cibus Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023

Company also reports continued progress of Cibus’ high-throughput soybean editing system and its two advanced traits for Sclerotinia resistance and HT2.

Key Points: 
  • Company also reports continued progress of Cibus’ high-throughput soybean editing system and its two advanced traits for Sclerotinia resistance and HT2.
  • ET
    SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the Company), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced its financial results for the quarter ended September 30, 2023, and provided a business update.
  • Peter Beetham, President and COO of Cibus, commented, "The third quarter is an important period for field studies.
  • Cibus will host a live webcast, Thursday, November 9, 2023, at 4:30 p.m. Eastern Standard Time to discuss its third quarter 2023 financial results and provide a business update.

Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy

Retrieved on: 
Tuesday, December 5, 2023

Arnaud Dubarry will be based in Strasbourg and will be responsible for all aspects of the Company’s financial strategy, management and operations to accelerate the development of its innovative immunotherapy pipeline.

Key Points: 
  • Arnaud Dubarry will be based in Strasbourg and will be responsible for all aspects of the Company’s financial strategy, management and operations to accelerate the development of its innovative immunotherapy pipeline.
  • Prior to joining Transgene, he served as Executive Finance Director at Gilead, where he led a major strategic transformation of the global finance function.
  • Alongside this new appointment, Transgene has promoted Lucie Larguier to Vice President Corporate Communications and Investor Relations with immediate effect.
  • I am looking forward to contributing to shaping the company's future and collaborating with the entire team to build on its success.”